



The 12th International Kawasaki Disease Symposium

Sponsored Symposium

Date : 14:40-16:10 Thursday June 14 , 2018
Venue : Room1 (501+502), 5th Floor,
PACIFICO Yokohama, Conference Center
1-1-1, Minato Mirai, Nishi-ku, Yokohama 220-0012, JAPAN

Theme: Alternative treatment

Moderator:

Keiji Tsuchiya (Department of Pediatrics, Japanese Red Cross Medical Center)

Adriana H. Tremoulet (Department of Pediatrics, University of California San Diego)

Lecture 1 (Keynote) 20 min.

Current status of biologic product clinical trials for acute Kawasaki disease in the U.S.

Jane C. Burns (Department of Pediatrics, University of California San Diego)

Lecture 2 15 min.

Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan

Tohru Kobayashi (Department of Management and Strategy, Clinical Research Center, National Center for Child Health and Development)

Lecture 3 15 min.

Therapies targeting TNF-alpha against IVIG resistant Kawasaki disease; infliximab and plasma exchange

Shuichi Ito (Department of Pediatrics, Graduate School of Medicine, Yokohama City University)

Lecture 4 15 min.

Progress of a randomized trial of immunoglobulin plus cyclosporin A in patients with Kawasaki disease who are predicted to be non-responders to initial treatment (KAICA Trial)

Hikomichi Hamada (Chiba University Graduate School of Medicine and Department of Pediatrics, Tokyo Women's Medical University Yachiyo Medical Center)

Lecture 5 15 min.

Prospective Observational Study on Efficacy and Safety of Stratified Treatment with Immunoglobulin Plus Steroid for Kawasaki Disease (Post RAISE)

Koichi Miyata (Department of Cardiology, Tokyo Metropolitan Children's Medical Center)

Cosponsored by: The 12th International Kawasaki Disease Symposium
Mitsubishi Tanabe Pharma Corporation